Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa. – PubMed – NCBI

Int J Clin Pharm. 2016 Feb;38(1):70-9. Comparative Study; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov’t

Source: Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa. – PubMed – NCBI

Duration of Antibiotic Treatment in Community-Acquired Pneumonia | Guidelines | JAMA Internal Medicine | The JAMA Network

This noninferiority trial compares the effects of IDSA/ATS guideline–recommended vs conventional antibiotic treatment duration on symptom and clinical resolution in hospitalized patients with community-acquired pneumonia.

Source: Duration of Antibiotic Treatment in Community-Acquired Pneumonia | Guidelines | JAMA Internal Medicine | The JAMA Network

Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study

Source: Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study

An institutional comparison of total abdominal colectomy and diverting loop ileostomy and colonic lavage in the treatment of severe, complicated Clostridium difficile infections

Source: An institutional comparison of total abdominal colectomy and diverting loop ileostomy and colonic lavage in the treatment of severe, complicated Clostridium difficile infections

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial – The Lancet Infectious Diseases

A dose of 35 mg/kg rifampicin was safe, reduced the time to culture conversion inliquid media, and could be a promising component of future, shorter regimens. Ouradaptive trial design was successfully implemented in a multi-centre, high tuberculosisburden setting, and could speed regimen development at reduced cost.

Source: High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial – The Lancet Infectious Diseases